Laboratory-wide association study of survival with prostate cancer.
Laboratory-wide association study of survival with prostate cancer.
复制标题
DOI：
10.1002/cncr.33341
复制
发表时间：
2021-04-01
期刊：
影响因子：
6.2
通讯作者：
Leppert, John T.
中科院分区：
文献类型：
--
作者：
Sohlberg, Ericka M.;Thomas, I-Chun;Yang, Jaden;Kapphahn, Kristopher;Velaer, Kyla N.;Goldstein, Mary K.;Wagner, Todd H.;Chertow, Glenn M.;Brooks, James D.;Patel, Chirag J.;Desai, Manisha;Leppert, John T.
对患者整体健康状况的估计对于为诊断为癌症的患者做出治疗决策至关重要。作者应用 XWAS 方法（本文称为“实验室范围关联研究 (LWAS)”）来评估常规收集的实验室测试与患有前列腺癌的退伍军人的生存之间的关联。作者利用诊断后 6 个月内收集的任何实验室检测结果，确定了退伍军人健康管理局 2000 年至 2013 年间被诊断患有前列腺癌的 133,878 名患者（3,345,083 个结果）。使用 LWAS 框架，使用错误发现率来测试多个实验室测试与生存之间的关联，并使用训练、测试和验证队列对这些结果进行验证。总共 31 项与生存相关的实验室测试符合严格的 LWAS 标准。 LWAS 证实了前列腺癌生物学标志物（前列腺特异性抗原：风险比 [HR]，1.07 [95% 置信区间 (95% CI)，1.06–1.08]；碱性磷酸酶：HR，1.22 [95% CI，1.20–1.24]）以及一般健康状况的实验室测试（例如，血清白蛋白：HR，0.78 [95% CI， 0.76–0.80]；肌酐：HR，1.05 [95% CI，1.03–1.07]）和炎症（白细胞计数：HR，1.23 [95% CI，1.98–1.26]；红细胞沉降率：HR，1.33 [95% CI，1.09–1.61]）。此外，作者还针对局部和晚期疾病患者导出并验证了单独的模型，在每个队列中分别确定了 28 种实验室标记物和 15 种实验室标记物。作者使用 LWAS 方法确定了常规收集的与前列腺癌患者生存相关的实验室数据，包括前列腺癌生物学、整体健康状况和炎症的标志物。将生存决定因素的考虑范围扩大到与癌症本身相关的因素之外，有助于为临床试验的设计提供信息，并有助于共同决策。本文研究了与前列腺癌退伍军人生存相关的常规实验室测试。通过实验室范围内的关联研究，作者确定了 31 项与生存相关的实验室测试，可用于为临床试验的设计提供信息并帮助患者共同决策。
Estimates of overall patient health are essential to inform treatment decisions for patients diagnosed with cancer. The authors applied XWAS methods, herein referred to as “laboratory-wide association study (LWAS)”, to evaluate associations between routinely collected laboratory tests and survival in veterans with prostate cancer. The authors identified 133,878 patients who were diagnosed with prostate cancer between 2000 and 2013 in the Veterans Health Administration using any laboratory tests collected within 6 months of diagnosis (3,345,083 results). Using the LWAS framework, the false-discovery rate was used to test the association between multiple laboratory tests and survival, and these results were validated using training, testing, and validation cohorts. A total of 31 laboratory tests associated with survival met stringent LWAS criteria. LWAS confirmed markers of prostate cancer biology (prostate-specific antigen: hazard ratio [HR], 1.07 [95% confidence interval (95% CI), 1.06–1.08]; and alkaline phosphatase: HR, 1.22 [95% CI, 1.20–1.24]) as well laboratory tests of general health (eg, serum albumin: HR, 0.78 [95% CI, 0.76–0.80]; and creatinine: HR, 1.05 [95% CI, 1.03–1.07]) and inflammation (leukocyte count: HR, 1.23 [95% CI, 1.98–1.26]; and erythrocyte sedimentation rate: HR, 1.33 [95% CI, 1.09–1.61]). In addition, the authors derived and validated separate models for patients with localized and advanced disease, identifying 28 laboratory markers and 15 laboratory markers, respectively, in each cohort. The authors identified routinely collected laboratory data associated with survival for patients with prostate cancer using LWAS methodologies, including markers of prostate cancer biology, overall health, and inflammation. Broadening consideration of determinants of survival beyond those related to cancer itself could help to inform the design of clinical trials and aid in shared decision making. This article examined routine laboratory tests associated with survival among veterans with prostate cancer. Using laboratory-wide association studies, the authors identified 31 laboratory tests associated with survival that can be used to inform the design of clinical trials and aid patients in shared decision making.
登录
查看更多内容
影响因子：
--
作者：
Belderbos BPS;de Wit R;Hoop EO;Nieuweboer A;Hamberg P;van Alphen RJ;Bergman A;van der Meer N;Bins S;Mathijssen RHJ;van Soest RJ
通讯作者：
van Soest RJ
影响因子：
7.2
作者：
DEYO, RA;CHERKIN, DC;CIOL, MA
通讯作者：
CIOL, MA
影响因子：
105.7
作者：
Collins, Gary S.;Reitsma, Johannes B.;Moons, Karel G. M.
通讯作者：
Moons, Karel G. M.
影响因子：
2.8
作者：
Nadal, Rosa;Tsai, Hua-Ling;Eisenberger, Mario A.
通讯作者：
Eisenberger, Mario A.
影响因子：
3.5
作者：
Naggara, O.;Raymond, J.;Altman, D. G.
通讯作者：
Altman, D. G.